Patients & Caregivers

Clinical Trials

Advancing Multiple Global Clinicals for Obexelimab and Orelabrutinib to Treat Autoimmune Diseases

• Immunoglobulin G4-Related Disease (IgG4-RD)

  Trial Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO) Trial Number: NCT05662241 Stage: Phase 3 Status: Target Enrollment Complete

• Primary Progressive Multiple Sclerosis (PPMS)

  Trial Title: A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis Trial Number: NCT07067463 Stage: Phase 3 Status: Initiated 3Q 2025

• Secondary Progressive Multiple Sclerosis (SPMS)

  Trial Title: A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis Trial Number: To be determined Stage: Phase 3 (planned) Status: Expected to initiate in 1Q 2026

• Relapsing Multiple Sclerosis (RMS)

  Trial Title: A Phase 2 double-blinded, randomized, placebo-controlled study assessing efficacy and safety of obexelimab, in patients with Relapsing Multiple Sclerosis (MoonStone) Trial Number: NCT06564311 Stage: Phase 2 Status: Positive 12-week primary endpoint data reported

• Systemic Lupus Erythematosus (SLE)

  Trial Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus (SunStone) Trial Number: NCT06559163 Stage: Phase 2 Status: Enrolling